Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08QKJ
|
|||
| Former ID |
DIB005553
|
|||
| Drug Name |
Stanozolol
|
|||
| Synonyms |
stanozolol; Androstanazole; Winstrol; Androstanazol; 10418-03-8; Stromba; Stanazolol; Winstrol Depot; Strombaject; Tevabolin; Estazol; Winstroid; Anabol; Winstrol V; Estanozolol; Stanozololum; Stanozolo [DCIT]; Androstanazole (VAN); WIN 14833; Stanozolol (1'H form); Winstrol-V; Stanozololum [INN-Latin]; Estanozolol [INN-Spanish]; UNII-4R1VB9P8V3; Androstanazolestanazol; HSDB 3185; Stanozolol (2'H form); EINECS 233-894-8; NSC 43193; NSC 233046; 4R1VB9P8V3; CHEBI:9249; 2'H-Androst-2-eno(3,2-c)pyrazol-17-ol, 17-methyl-, (5alpha,17beta)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hereditary angioedema [ICD-11: 4A00.14; ICD-9: 277.6] | Approved | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H32N2O
|
|||
| Canonical SMILES |
CC12CCC3C(C1CCC2(C)O)CCC4C3(CC5=C(C4)NN=C5)C
|
|||
| InChI |
1S/C21H32N2O/c1-19-11-13-12-22-23-18(13)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,24H,4-11H2,1-3H3,(H,22,23)/t14-,15+,16-,17-,19-,20-,21-/m0/s1
|
|||
| InChIKey |
LKAJKIOFIWVMDJ-IYRCEVNGSA-N
|
|||
| CAS Number |
CAS 302-96-5
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:9249
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
|
Studied Microbe: Collinsella aerofaciens
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Collinsella aerofaciens was decreased by Stanozolol (adjusted p-values: 8.78E-03). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia obeum
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Blautia obeum was decreased by Stanozolol (adjusted p-values: 3.95E-06). | |||
|
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Coprococcus comes was decreased by Stanozolol (adjusted p-values: 3.70E-05). | |||
|
Studied Microbe: Dorea formicigenerans
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Dorea formicigenerans was decreased by Stanozolol (adjusted p-values: 7.27E-06). | |||
|
Studied Microbe: Eubacterium eligens
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium eligens was decreased by Stanozolol (adjusted p-values: 5.29E-03). | |||
|
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium rectale was decreased by Stanozolol (adjusted p-values: 4.40E-04). | |||
|
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia intestinalis was decreased by Stanozolol (adjusted p-values: 2.70E-04). | |||
|
Studied Microbe: Ruminococcus bromii
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus bromii was decreased by Stanozolol (adjusted p-values: 1.52E-05). | |||
|
Studied Microbe: Ruminococcus torques
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus torques was decreased by Stanozolol (adjusted p-values: 2.55E-05). | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.